Affinage

WDFY4

WD repeat- and FYVE domain-containing protein 4 · UniProt Q6ZS81

Length
3184 aa
Mass
353.6 kDa
Annotated
2026-04-28
16 papers in source corpus 9 papers cited in narrative 9 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

WDFY4 is a BEACH domain-containing protein that serves as a central regulator of antigen cross-presentation and immune cell homeostasis. It is essential for cross-presentation of cell-associated and immune-complex antigens by both cDC1 and cDC2 dendritic cell subsets to CD8+ T cells, enabling antiviral immunity and tumor rejection without affecting MHC-II presentation or dendritic cell development (PMID:30409884, PMID:39918736, PMID:36940342). Beyond dendritic cells, WDFY4 regulates B cell noncanonical autophagy and development, CD8+ T cell survival through a ROS/p53/ERK axis, Th2 differentiation, and innate NF-κB signaling downstream of TLR3/4/9 and MDA5 (PMID:30257884, PMID:34482201, PMID:34425575, PMID:29331962). WDFY4 expression is transcriptionally controlled by YY1 binding at an SLE-associated intronic variant, linking reduced WDFY4 levels to systemic lupus erythematosus susceptibility (PMID:22972472).

Mechanistic history

Synthesis pass · year-by-year structured walk · 9 steps
  1. 2012 Medium

    Establishing how a disease-associated variant regulates WDFY4 expression resolved the question of whether SLE risk SNPs in WDFY4 are functionally consequential at the transcriptional level.

    Evidence EMSA, ChIP, luciferase reporter assays, and YY1 knockdown/overexpression in human cells showing YY1 binding at rs877819 controls WDFY4 transcription

    PMID:22972472

    Open questions at the time
    • Which immune cell types are most affected by reduced WDFY4 transcription in vivo remains undefined
    • Whether other transcription factors co-regulate WDFY4 at this locus is untested
  2. 2018 High

    Identification of WDFY4 as an essential, specific mediator of cross-presentation in cDC1s established its core molecular function — enabling MHC-I loading of exogenous antigens without affecting MHC-II presentation, cDC1 development, or IL-12 production.

    Evidence CRISPR screen in cDC1 line and Wdfy4-/- mice with viral, parasitic, and tumor antigen challenge models

    PMID:30409884

    Open questions at the time
    • The precise molecular step in the cross-presentation pathway where WDFY4 acts (e.g., phagosome-to-cytosol export, proteasomal access, peptide loading) is unknown
    • Whether WDFY4 functions as a scaffold, transporter, or membrane remodeler has not been determined
  3. 2018 Medium

    Demonstrating that WDFY4 physically interacts with TLR3/4/9 and MDA5 and augments NF-κB activation revealed a second functional axis beyond cross-presentation — amplification of innate immune signaling.

    Evidence Co-immunoprecipitation with TLRs and MDA5, NF-κB luciferase reporter assays, and apoptosis assays showing enhanced MDA5-induced apoptosis by truncated WDFY4

    PMID:29331962

    Open questions at the time
    • Interactions validated by Co-IP only without reciprocal pull-down or endogenous IP in primary cells
    • Mechanism by which WDFY4 augments NF-κB (scaffolding vs. signalosome assembly) is not defined
    • Relevance of truncated isoform in physiological settings beyond overexpression systems is unclear
  4. 2018 Medium

    Conditional deletion in B cells revealed that WDFY4 restrains noncanonical autophagy (LC3 lipidation independent of p62/Beclin1) and is required for normal B cell development and humoral immunity, connecting it to SLE pathogenesis.

    Evidence B cell-conditional Wdfy4 knockout mice with LC3 lipidation assays, B cell subset flow cytometry, pristane-induced lupus model

    PMID:30257884

    Open questions at the time
    • Molecular targets of WDFY4-regulated noncanonical autophagy in B cells are uncharacterized
    • Whether the autophagy phenotype in B cells relates mechanistically to the cross-presentation function in DCs is unknown
  5. 2021 Medium

    T cell-conditional knockout established that WDFY4 maintains CD8+ T cell survival by suppressing ROS/Nox2 accumulation and p53-mediated apoptosis while sustaining ERK signaling, broadening its function beyond antigen-presenting cells.

    Evidence T cell-conditional Wdfy4 KO mice with ROS quantification, apoptosis assays, p53/ERK pathway analysis, and transplantable tumor models

    PMID:34482201

    Open questions at the time
    • Direct molecular link between WDFY4 and Nox2/ROS regulation is not established
    • Single-lab finding; independent replication lacking
  6. 2021 Medium

    Showing that WDFY4 loss promotes Th2 differentiation and exacerbates allergic asthma extended its immune-regulatory role to CD4+ T helper cell polarization.

    Evidence Wdfy4-/- mice with in vitro Th2 differentiation and OVA-induced asthma model

    PMID:34425575

    Open questions at the time
    • Mechanism by which WDFY4 suppresses Th2 polarization (transcription factor regulation, cytokine signaling) is not defined
    • Single-lab study without independent confirmation
  7. 2023 High

    Demonstrating that WDFY4 deficiency in NOD mice prevents autoimmune diabetes by abolishing cross-presentation of islet antigens proved that WDFY4-dependent cross-presentation is the critical gateway for autoreactive CD8+ T cell priming in organ-specific autoimmunity.

    Evidence CRISPR/Cas9 Wdfy4-/- NOD mice with diabetes incidence monitoring, insulitis histology, and cross-presentation/T cell priming assays

    PMID:36940342

    Open questions at the time
    • Whether therapeutic targeting of WDFY4 can reverse established autoimmunity is untested
    • The specific islet antigens cross-presented via WDFY4 are not identified
  8. 2025 High

    Extending WDFY4-dependent cross-presentation to cDC2s demonstrated that this function is not cDC1-exclusive, fundamentally revising the model of which DC subsets require WDFY4 for CD8+ T cell priming.

    Evidence cDC1-deficient, cDC2-deficient, and Wdfy4-/- genetic mouse models with immune complex vaccination and tumor rejection assays

    PMID:39918736

    Open questions at the time
    • Whether WDFY4 operates through the same molecular mechanism in cDC2s as in cDC1s is not established
    • The antigen forms (particulate vs. soluble vs. immune complex) that differentially engage WDFY4 in each DC subset remain unclear
  9. 2025 Medium

    Discovery of a WDFY4–LAPTM5 interaction that promotes endothelial ferroptosis via suppression of the CDC42/mTOR/4EBP1/SLC7A11 axis revealed a non-immune function in vascular biology and atherosclerosis.

    Evidence Co-IP, co-localization, endothelium-specific WDFY4 knockout in ApoE-/- mice on HFD with pathway inhibitor rescue

    PMID:40755163

    Open questions at the time
    • Single-lab finding; endothelial ferroptosis link not independently replicated
    • Whether the LAPTM5 interaction is relevant to WDFY4's immune cell functions is unknown
    • Structural basis for WDFY4–LAPTM5 interaction not determined

Open questions

Synthesis pass · forward-looking unresolved questions
  • The precise molecular step at which WDFY4 acts in the cross-presentation pathway — whether it facilitates antigen escape from endosomes, phagosomal membrane integrity, peptide–MHC-I loading, or vesicular trafficking — remains the central unresolved question.
  • No structural model of WDFY4 or its BEACH domain in the context of cross-presentation machinery exists
  • Direct substrates or cargo of WDFY4 in DCs have not been identified
  • Relationship between WDFY4's roles in autophagy regulation, innate signaling, and cross-presentation is mechanistically unintegrated

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060090 molecular adaptor activity 2
Localization
GO:0005764 lysosome 1 GO:0005829 cytosol 1
Pathway
R-HSA-168256 Immune System 7 R-HSA-5357801 Programmed Cell Death 2 R-HSA-9612973 Autophagy 1

Evidence

Reading pass · 9 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2018 WDFY4, a BEACH domain-containing protein, is essential for cross-presentation of cell-associated antigens by Batf3-dependent cDC1s (CD8α+/XCR1+ classical dendritic cells) to CD8+ T cells in mice, identified via a functional CRISPR screen. WDFY4 knockout mice fail to prime virus-specific CD8+ T cells in vivo and cannot induce tumor rejection, but retain normal cDC1 populations, MHC-II presentation, and IL-12 production, demonstrating a specific role in the cross-presentation pathway rather than cDC1 development. CRISPR screen, Wdfy4-/- mouse knockout, in vivo CD8+ T cell priming assays, tumor rejection assays, flow cytometry, Toxoplasma infection model Science (New York, N.Y.) High 30409884
2025 WDFY4-dependent cross-presentation is not exclusive to cDC1s; cDC2s also use a WDFY4-dependent pathway to cross-present immune complex antigens to CD8+ T cells in vivo, enabling tumor rejection even in the absence of cDC1s. Monocyte-derived DCs do not participate in this WDFY4-dependent cross-presentation. Genetic mouse models (cDC1-deficient, cDC2-deficient, Wdfy4-/- mice), immune complex vaccination, in vivo CD8+ T cell priming, tumor rejection assays The Journal of experimental medicine High 39918736
2018 Both full-length WDFY4 and a truncated isoform (tr-WDFY4) physically interact with pattern recognition receptors TLR3, TLR4, TLR9, and MDA5, and augment NF-κB activation downstream of these receptors. The truncated isoform (encoded by the CADM-risk allele) also enhances MDA5-induced apoptosis more than full-length WDFY4. Co-immunoprecipitation (interaction with TLRs and MDA5), NF-κB reporter assays, apoptosis assays, trans-eQTL analysis Annals of the rheumatic diseases Medium 29331962
2018 In B cells, WDFY4 facilitates noncanonical autophagic activity. Loss of WDFY4 in B cells (conditional knockout) increases LC3 lipidation independently of p62 and Beclin1 (canonical autophagy markers), and leads to defects in B cell development (pro- to pre-B cell transition), reduced peripheral B cell numbers, impaired antibody responses, and amelioration of SLE phenotypes including autoantibody production and glomerulonephritis. B cell-conditional Wdfy4 knockout mice, LC3 lipidation assay, flow cytometry of B cell subsets, pristane-induced SLE model, antibody response assays Journal of immunology (Baltimore, Md. : 1950) Medium 30257884
2023 In NOD mice, WDFY4 deficiency (via CRISPR/Cas9) abolishes cross-presentation of cell-associated antigens by cDC1s, preventing priming of autoreactive CD8+ T cells, and as a consequence blocks recruitment of autoreactive CD4+ T cells into islets and prevents autoimmune diabetes, while MHC-II antigen presentation and CD4+ T cell activation in lymph nodes remain intact. CRISPR/Cas9 Wdfy4-/- NOD mice, cross-presentation assays, diabetes incidence monitoring, insulitis histology, T cell priming assays Proceedings of the National Academy of Sciences of the United States of America High 36940342
2021 Selective deficiency of WDFY4 in T cells leads to reduced CD8+ T cell numbers in the periphery, enhanced CD8+ T cell apoptosis, elevated intracellular reactive oxygen species (ROS) with upregulation of Nox2, and activation of the p53 pathway with inhibition of the ERK pathway. This results in impaired antitumor CD8+ T cell responses. T cell-conditional Wdfy4 knockout mice, flow cytometry, ROS measurement, apoptosis assays, p53/ERK pathway analysis, transplantable tumor model Molecular immunology Medium 34482201
2021 WDFY4 deficiency in mice promotes Th2 cell differentiation and Th2 cytokine production in vitro and in vivo, and exacerbates ovalbumin-induced asthma with enhanced inflammatory cell infiltration, goblet cell hyperplasia, mucus production, and collagen deposition. Wdfy4-/- mouse model, in vitro Th2 differentiation from naïve CD4+ T cells, OVA-induced asthma model, cytokine measurement, histology International archives of allergy and immunology Medium 34425575
2025 WDFY4 interacts with lysosomal transmembrane protein LAPTM5, validated by co-immunoprecipitation and immunofluorescence co-localization, and this interaction promotes ferroptosis in endothelial cells. Mechanistically, WDFY4 promotes LAPTM5 expression, which suppresses the CDC42/mTOR/4EBP1/SLC7A11 pathway to enhance ferroptosis. Endothelial-specific WDFY4 knockout reduces atherosclerotic plaque formation in ApoE-/- mice. Co-immunoprecipitation, immunofluorescence co-localization, WDFY4 knockdown/knockout in vitro and in vivo (endothelium-specific transgenic mice), ApoE-/- HFD atherosclerosis model, pathway inhibitor rescue experiments Journal of cellular and molecular medicine Medium 40755163
2012 The transcription factor YY1 (Yinyang1) binds to an intronic SLE-associated variant site (rs877819) in WDFY4; the risk allele (A) reduces YY1 binding affinity, resulting in lower transcriptional activity of WDFY4. WDFY4 is significantly downregulated in SLE patients carrying this allele. Electrophoretic mobility shift assay (EMSA), supershift assay, dual-luciferase reporter assay, YY1 siRNA knockdown and overexpression, chromatin immunoprecipitation (ChIP), allelic expression analysis Genes and immunity Medium 22972472

Source papers

Stage 0 corpus · 16 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2010 Genome-wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus. PLoS genetics 343 20169177
2018 WDFY4 is required for cross-presentation in response to viral and tumor antigens. Science (New York, N.Y.) 264 30409884
2018 Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. Annals of the rheumatic diseases 63 29331962
2012 An intronic variant associated with systemic lupus erythematosus changes the binding affinity of Yinyang1 to downregulate WDFY4. Genes and immunity 45 22972472
2018 WDFY4 Is Involved in Symptoms of Systemic Lupus Erythematosus by Modulating B Cell Fate via Noncanonical Autophagy. Journal of immunology (Baltimore, Md. : 1950) 28 30257884
2023 WDFY4 polymorphisms in Chinese patients with anti-MDA5 dermatomyositis is associated with rapid progressive interstitial lung disease. Rheumatology (Oxford, England) 18 36637178
2014 E26 transformation-specific-1 (ETS1) and WDFY family member 4 (WDFY4) polymorphisms in Chinese patients with rheumatoid arthritis. International journal of molecular sciences 15 24549174
2021 Deficiency in WDFY4 reduces the number of CD8+ T cells via reactive oxygen species-induced apoptosis. Molecular immunology 14 34482201
2025 Shared pathway of WDFY4-dependent cross-presentation of immune complexes by cDC1 and cDC2. The Journal of experimental medicine 10 39918736
2023 WDFY4 deficiency in NOD mice ameliorates autoimmune diabetes and insulitis. Proceedings of the National Academy of Sciences of the United States of America 9 36940342
2023 Ferroptosis and WDFY4 as novel targets for immunotherapy of lung adenocarcinoma. Aging 8 37728413
2024 The clinical relevance of WDFY4 in autoimmune diseases in diverse ancestral populations. Rheumatology (Oxford, England) 7 38507703
2020 BVVL/ FL: features caused by SLC52A3 mutations; WDFY4 and TNFSF13B may be novel causative genes. Neurobiology of aging 7 33189404
2021 Lack of WDFY4 Aggravates Ovalbumin-Induced Asthma via Enhanced Th2 Cell Differentiation. International archives of allergy and immunology 6 34425575
2025 WDFY4 Promotes the Progression of Atherosclerosis by Regulating Ferroptosis Mediated by the LAPTM5/CDC42/mTOR/4EBP1/SLC7A11 Pathway. Journal of cellular and molecular medicine 2 40755163
2026 Epigenetic alterations in WDFY4 DNA methylation are linked to immunoinflammatory processes in rheumatoid arthritis: insights from a case-control study. Clinical rheumatology 0 41965494